Sakar Healthcare Limited Total Assets

Latest as of March 2026: Rs4.81 Billion INR ≈ $52.02 Million USD

Sakar Healthcare Limited total assets. Based on the latest financial reports, Sakar Healthcare Limited (SAKAR) holds total assets worth Rs4.81 Billion INR (≈ $52.02 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Sakar Healthcare Limited market capitalisation for the company's overall valuation and market capitalisation.

Total Assets of Sakar Healthcare Limited (2010–2026)

Total assets of Sakar Healthcare Limited from 2010 to 2026. This chart illustrates how Sakar Healthcare Limited's total assets have evolved over time, based on quarterly financial data. See Sakar Healthcare Limited stock price for real-time trading data and today's change.

Sakar Healthcare Limited - Asset Composition Analysis

Sakar Healthcare Limited Total Assets Breakdown (March 2026)

Sakar Healthcare Limited total assets breakdown as of March 2026. Sakar Healthcare Limited's total assets of Rs4.81 Billion consist of 29.2% current assets and 70.8% non-current assets.

Asset Category Amount (INR) % of Total Assets
Cash & Equivalents Rs0.00 0.1%
Accounts Receivable Rs500.83 Million 10.4%
Inventory Rs700.41 Million 14.6%
Property, Plant & Equipment Rs0.00 0.0%
Intangible Assets Rs74.27 Million 1.5%
Goodwill Rs0.00 0.0%

Asset Composition Trend (2010–2026)

This chart illustrates how Sakar Healthcare Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Sakar Healthcare Limited (SAKAR) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Sakar Healthcare Limited's current assets represent 29.2% of total assets in 2026, a decrease from 30.9% in 2010.
  • Cash Position: Cash and equivalents constituted 0.1% of total assets in 2026, down from 0.6% in 2010.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2010.
  • Asset Diversification: The largest asset category is inventory at 14.6% of total assets.

Sakar Healthcare Limited Competitors by Total Assets

Key competitors of Sakar Healthcare Limited based on total assets are shown below.

Company Country Total Assets
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
China CN¥9.54 Billion
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
China CN¥6.44 Billion
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
China CN¥1.54 Billion
Renhe Pharmacy Co Ltd
SHE:000650
China CN¥7.93 Billion
Bide Pharmatech Co. Ltd. A
SHG:688073
China CN¥2.54 Billion
Jianmin Pharmaceutical Group Co Ltd
SHG:600976
China CN¥4.69 Billion
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
China CN¥2.26 Billion
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
China CN¥25.73 Billion

Sakar Healthcare Limited - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 1.28 1.40 1.01
Quick Ratio 0.64 0.71 0.54
Cash Ratio 0.00 0.00 0.00
Working Capital Rs309.21 Million Rs255.41 Million Rs4.54 Million

Sakar Healthcare Limited - Advanced Valuation Insights

This section examines the relationship between Sakar Healthcare Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 6.26
Latest Market Cap to Assets Ratio 0.05
Asset Growth Rate (YoY) 15.8%
Total Assets Rs4.81 Billion
Market Capitalization $224.22 Million USD

Valuation Analysis

Below Book Valuation: The market values Sakar Healthcare Limited's assets below their book value (0.05x), which may indicate investor concerns about asset quality or future growth.

Rapid Asset Growth: Sakar Healthcare Limited's assets grew by 15.8% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for Sakar Healthcare Limited (2010–2026)

The table below shows the annual total assets of Sakar Healthcare Limited from 2010 to 2026.

Year Total Assets Change
2026-03-31 Rs4.81 Billion
≈ $52.02 Million
+15.83%
2025-03-31 Rs4.15 Billion
≈ $44.91 Million
+6.84%
2024-03-31 Rs3.89 Billion
≈ $42.03 Million
+15.56%
2023-03-31 Rs3.36 Billion
≈ $36.37 Million
+25.61%
2022-03-31 Rs2.68 Billion
≈ $28.96 Million
+50.61%
2021-03-31 Rs1.78 Billion
≈ $19.23 Million
+54.44%
2020-03-31 Rs1.15 Billion
≈ $12.45 Million
+16.66%
2019-03-31 Rs986.85 Million
≈ $10.67 Million
+21.68%
2018-03-31 Rs811.00 Million
≈ $8.77 Million
+14.89%
2017-03-31 Rs705.87 Million
≈ $7.63 Million
+38.11%
2016-03-31 Rs511.10 Million
≈ $5.53 Million
+1.86%
2015-03-31 Rs501.75 Million
≈ $5.43 Million
-4.13%
2014-03-31 Rs523.37 Million
≈ $5.66 Million
+4.48%
2013-03-31 Rs500.94 Million
≈ $5.42 Million
+0.35%
2012-03-31 Rs499.20 Million
≈ $5.40 Million
+2.11%
2011-03-31 Rs488.89 Million
≈ $5.29 Million
+9.29%
2010-03-31 Rs447.35 Million
≈ $4.84 Million
--

About Sakar Healthcare Limited

NSE:SAKAR India Drug Manufacturers - Specialty & Generic
Market Cap
$224.22 Million
Rs20.73 Billion INR
Market Cap Rank
#15915 Global
#810 in India
Share Price
Rs944.55
Change (1 day)
+1.08%
52-Week Range
Rs361.90 - Rs1188.40
All Time High
Rs1188.40
About

Sakar Healthcare Limited research, develops, manufactures, and sells pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups and injections, liquid injectable (SVP) in ampoules, vials and lyophilized injections, and oral solid dosages. Its product portfolio consists of formulations in therapeutic areas, such as anti-infective, analge… Read more